A review of the use of histrelin acetate in the treatment of prostate cancer

BJU Int. 2009 Mar:103 Suppl 2:14-22. doi: 10.1111/j.1464-410X.2009.08384.x.

Author

E David Crawford¹

Affiliation

¹ University of Colorado Health Science Center, Aurora, CO 80045, USA. david.crawford@ucdenver.edu

PMID: 19228148
DOI: 10.1111/j.1464-410X.2009.08384.x

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Aged
Aged, 80 and over
Androgen Antagonists / administration & dosage*
Androgen Antagonists / adverse effects
Antineoplastic Agents, Hormonal / administration & dosage*
Antineoplastic Agents, Hormonal / adverse effects
Clinical Trials as Topic
Drug Implants
Gonadotropin-Releasing Hormone / administration & dosage
Gonadotropin-Releasing Hormone / adverse effects
Gonadotropin-Releasing Hormone / analogs & derivatives*
Humans
Male
Middle Aged
Prostatic Neoplasms / drug therapy*
Treatment Outcome

Substances

Androgen Antagonists
Antineoplastic Agents, Hormonal
Drug Implants
Gonadotropin-Releasing Hormone
histrelin